TABLE II.

Effect of omalizumab on TLR7^* expression in unstimulated PBMCs and pDCs^†

Mechanistic parameter			Omalizumab			Omalizumab		Placebo
Cell type	Method measured	Readout*	No.	Prerandomization, mean (SD)	Postrandomization, mean (SD)	Ratio of geometric means (95% CI)	P value	No.	Prerandomization, mean (SD)	Postrandomization, mean (SD)	Ratio of geometric means (95% CI)	P value
PBMC	RT-PCR	TLR7 mRNA	64	1.2 (1.6)	1.0 (1.8)	0.81 (0.71–0.92)	.002	23	1.3 (1.6)	1.2 (2.0)	0.92 (0.72–1.18)	.50
Purified pDC	RT-PCR	TLR7 mRNA	18	0.3 (1.7)	0.2 (1.5)	0.79 (0.66–0.93)	.008	7	0.2 (1.4)	0.2 (1.8)	0.89 (0.62–1.29)	.47

Boldface indicates P < .05.

^*TLR7 mRNA values represent expression measured before ex vivo stimulation and normalized to HPRT expression (2^−Δct).

^†Means are geometric means, and SDs are geometric SDs.